IntelliPharmaCeutics (EM)【IPCIQ】銘柄情報

IntelliPharmaCeutics International Inc (EM) (IPCIQ) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.000001

( - )

買値

0.00

売値

0.00

出来高

0.00 日の範囲 0.00

0.000001 52 週間の範囲 0.000001

時価総額

33.093

前日終値

0.000001

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 0

発行済株式数

33,092,665

配当利回り

PER

-0.55

1 株当たり利益 (EPS)

-0.09

歳入

904.95k

純利益

-3.17M

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products ... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada. 詳細を表示

セクター

業界

ウェブサイト

www.intellipharmaceutics.com

本社

Toronto, Canada

設立

1998

IntelliPharmaCeutics International Inc (EM) is listed in the sector of the その他OTC with ticker IPCIQ. The last closing price for IntelliPharmaCeutics (EM) was US$0. Over the last year, IntelliPharmaCeutics (EM) shares have traded in a share price range of US$ 0.000001 to US$ 0.000001.

IntelliPharmaCeutics (EM) currently has 33,092,665 shares in issue. The market capitalisation of IntelliPharmaCeutics (EM) is US$33.09 . IntelliPharmaCeutics (EM) has a price to earnings ratio (PE ratio) of -0.55.

表示するニュースはありません。

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	CS
4	0	0	0	0	0	CS
12	1.0E-6	1.0E-6	1.0E-6	0	0	CS
26	1.0E-6	1.0E-6	1.0E-6	2399	1.0E-6	CS
52	1.0E-6	1.0E-6	1.0E-6	59111	1.0E-6	CS
156	1.0E-6	0.0001	1.0E-6	52592	1.0E-6	CS
260	1.0E-6	0.0001	1.0E-6	52592	1.0E-6	CS